GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Notes Receivable

PBIGF (Paradigm Biopharmaceuticals) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Notes Receivable?

Paradigm Biopharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Paradigm Biopharmaceuticals Notes Receivable Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Notes Receivable Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Paradigm Biopharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Paradigm Biopharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.